Providence Wealth Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Providence Wealth Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58.9K	Hold	25,000	–	–	0.03%	82
2026 Q1	$43.3K	Hold	25,000	–	–	0.03%	79
2025 Q4	$104K	Hold	25,000	–	–	0.07%	82
2025 Q3	$129K	Hold	25,000	–	–	0.08%	81
2025 Q2	$129K	Hold	25,000	–	–	0.09%	83
2025 Q1	$130K	Hold	25,000	–	–	0.1%	79
2024 Q4	$133K	Hold	25,000	–	–	0.1%	76
2024 Q3	$142K	Hold	25,000	–	–	0.11%	78
2024 Q2	$84K	Buy	25,000 +3,500	+16%	+$13.7K	0.07%	76
2024 Q1	$73.6K	Buy	21,500 +20,160	+1,504%	+$66.3K	0.06%	77
2023 Q4	$336K	Buy	+1,340	New	+$4.13K	0.3%	63

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Providence Wealth Advisors's ALDX Position: Q2 2026 in Review

Providence Wealth Advisors held its Aldeyra Therapeutics (ALDX) position steady in Q2 2026 at 25,000 shares worth $58.9K. The position accounts for 0.03% of the portfolio, ranked #82.

Providence Wealth Advisors first reported a position in ALDX in Q4 2023 and has held it in 11 quarters since. The position peaked at $336K in Q4 2023. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Providence Wealth Advisors held 25,000 shares of Aldeyra Therapeutics worth $58.9K as of Q2 2026.
Providence Wealth Advisors left its Aldeyra Therapeutics share count unchanged in Q2 2026.
Aldeyra Therapeutics made up 0.03% of Providence Wealth Advisors's portfolio in Q2 2026, its #82 holding.
Providence Wealth Advisors first reported a position in Aldeyra Therapeutics in Q4 2023 and has held it in 11 quarters since.
Providence Wealth Advisors's Aldeyra Therapeutics position peaked at $336K in Q4 2023.
107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Providence Wealth Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.